Bajaj Healthcare Limited (BAJAJHCARE) — Financial Results(2 announcements)

Investor Takeaways

Overall Tone: Cautious

Key Financial Highlights

What Changed

Bajaj Healthcare Limited reported a 69.9% year-on-year increase in revenue to ₹16,644.31 Cr for Q1 FY26, primarily attributed to strong operational performance. However, the company recorded a net loss of ₹1,369.80 Cr, driven by exceptional items and the reversal of ₹3,324.66 lakhs of prior-year revenue recognition amid Middle East instability. The board retained Mr. Gopalakrishnan Kesavan as Non-Executive Independent Director until 2030, pending shareholder approval. The auditor issued an unmodified limited review conclusion, confirming no material misstatements in the financials. The company utilized funds for loan repayment and capital expenditure, though specific utilization details were not elaborated.

Peer Comparison

Bajaj Healthcare’s P/E ratio of 44.89 is lower than Divi's Laboratories (72.41) and Torrent Pharmaceuticals (80.06), but higher than Sun Pharmaceutical (41.28). The company’s market capitalization is significantly smaller than its peers, indicating a more niche market presence.

Risks & Concerns

Quarterly Trend

[Not available]

CRITICAL: Quarterly trend data was not provided in the context. The Quarterly Trend section has been omitted per instructions.

Investor Takeaways

Overall Tone: Positive based on the numbers only.

Key Financial Highlights

What Changed

Bajaj Healthcare reported Q1 FY27 results showing revenue of ₹165.6 crores, up 11.3% year-on-year and 8.2% quarter-on-quarter. Net profit reached ₹13.7 crores, reflecting a 15.8% increase compared to the same quarter last year. The company recorded a gross profit of ₹80.4 crores, up 16.2% YoY, and EBITDA grew 16.4% YoY to ₹29.6 crores. The improvement in profitability was driven by growth in domestic API sales, which rose approximately 27% YoY. PAT margin expanded to 8.3% from 8.0% in the previous year. The company also highlighted regulatory milestones for Cenobamate tablets and ongoing expansion in research and development. These developments suggest progress in core product segments and increased operational momentum. The financial performance indicates strengthening demand in the pharmaceutical business, particularly in the API segment.

Peer Comparison

Bajaj Healthcare trades at a P/E ratio of 44.89, which is lower than Divi's Laboratories (72.41) and Torrent Pharmaceuticals (80.06), but higher than Sun Pharmaceutical (41.28). The company does not currently report ROE or ROCE figures in the provided fundamentals. Its market capitalization of ₹956.52 crores is significantly smaller than that of its peers, indicating a more niche market presence.

Risks & Concerns

Quarterly Trend

About Bajaj Healthcare Limited (BAJAJHCARE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

View full BAJAJHCARE stock details →